Anzeige
Mehr »
Login
Donnerstag, 29.02.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
InnoCan Pharma: Jetzt der Ausbruch aus dem Faultierkäfig?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0DNPW | ISIN: AU000000MSB8 | Ticker-Symbol: LWB
Tradegate
27.02.24
19:19 Uhr
0,170 Euro
-0,012
-6,59 %
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
MESOBLAST LIMITED Chart 1 Jahr
5-Tage-Chart
MESOBLAST LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,1700,18219:32
0,1700,18219:26

Aktuelle News zur MESOBLAST Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01:35Mesoblast share price tumbles on US$32.5m half-year loss1
00:18Mesoblast GAAP EPS of -$0.038 beats by $0.76, revenue of $3.39M misses by $0.41M2
00:01Mesoblast Limited: Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 202361NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update...
► Artikel lesen
DiMESOBLAST LIMITED: MSB Q2 Financial Results and Operational Highlights-
DiMESOBLAST LIMITED: Half Year Financial Results Presentation-
DiMESOBLAST LIMITED: Half Year Report and Accounts (including Appendix 4D)-
MoMesoblast Limited: Mesoblast Financial Results and Corporate Update Webcast3
MoMESOBLAST LIMITED: Mesoblast 2024 Half Year Financial Results Webcast2
15.02.Mesoblast gets FDA orphan drug status for Revascor3
15.02.US FDA grants Mesoblast orphan-drug designation for Revascor4
15.02.Australia's Mesoblast jumps as US FDA grants orphan-drug status to heart drug4
15.02.Mesoblast Limited: United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease98NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States...
► Artikel lesen
15.02.MESOBLAST LIMITED: FDA Grants Orphan Drug Designation for Revascor2
31.01.Mesoblast Limited: Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023155NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity...
► Artikel lesen
31.01.MESOBLAST LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report2
19.01.Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug2
19.01.Mesoblast up as FDA grants rare pediatric disease tag to cell therapy3
19.01.Mesoblast rises after cell therapy gets FDA rare pediatric disease designation3
19.01.Mesoblast receives coveted FDA designation for Revascor heart treatment4
19.01.ASX Health Stocks: Mesoblast rockets 20pc after being granted Rare Pediatric Disease Designation by FDA3
Seite:  Weiter >>
99 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1